



021104

16638 U.S. PTO

Practitioner's Docket No. : MPI02-107CN1M**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Mail Stop Patent Application**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

17497 U.S. PTO  
10/776871

021104

**NEW APPLICATION TRANSMITTAL**

Transmitted herewith for filing is the patent application of

Inventor(s): Rachel E. Meyers, Maria A. Glucksmann, and Laura A. Rudolph-Owen

For: **NOVEL HUMAN ENZYME FAMILY MEMBERS AND USES THEREOF****1. Type of Application**

This new application is for a(n)

- ☐ Original (nonprovisional)
- ☐ Design
- ☐ Plant
- ☐ Divisional.
- ☒ Continuation.
- ☐ Continuation-in-part (C-I-P).

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

- ☐ with sufficient postage as first class mail.

**37 C.F.R. SECTION 1.10\***

- ☒ as "Express Mail Post Office to Addressee"  
Mailing Label No. EV400464591US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

  
Sean Hunziker

(type or print name of person certifying)

Date: February 11, 2004

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).  
"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. : MPI02-107CN1M

**2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)**

- ☒ The new application being transmitted is a continuation of U.S. Application Serial No. 10/175,696, filed on June 20, 2002, which is: a continuation-in-part of U.S. Application Serial No. 10/067,668, filed February 4, 2002, which claims the benefit of U.S. Provisional Application Serial No. 60/266,140, filed February 2, 2001; a continuation-in-part of U.S. Application Serial No. 09/823,901, filed March 30, 2001, and a continuation-in-part of International Application Serial No. PCT/US01/10720, filed April 2, 2001, each of which claim the benefit of U.S. Provisional Application Serial No. 60/193,920, filed March 31, 2000; a continuation-in-part of U.S. Application Serial No. 09/862,658, filed May 21, 2001, and a continuation-in-part of International Application Serial No. PCT/US01/16380, filed May 21, 2001, each of which claims the benefit of U.S. Provisional Application Serial No. 60/205,675, filed May 19, 2000; and a continuation-in-part of U.S. Application Serial No. 09/882,837, filed June 15, 2001, and a continuation-in-part of International Application Serial No. PCT/US01/19319, filed June 15, 2001, each of which claims the benefit of U.S. Provisional Application Serial No. 60/211,727, filed June 15, 2000.

**3. Maintenance of Copendency of Prior Application**

A. ☐ Extension of time in prior application

B. ☐ Conditional Petition for Extension of Time in Prior Application

*(complete this item, if previous item not applicable)*

- ☐ A conditional petition for extension of time is being filed in the pending **prior** application.  
☐ A **copy** of the conditional petition filed in the prior application is attached.

**4. Abandonment of Prior Application (if applicable)**

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

**Notification in Parent Application of This Filing**

- ☐ A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

**5. Papers Enclosed**

**Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application**

470 Pages of Specification, including

1 Table of Contents

465 Pages of Description

3 Pages of Claims

1 Page of Abstract

27 Sheets of Drawings (Figure(s) 1, 2A, 2B, 3, 4A, 4B, 5, 6A, 6B, 6C, 7-8, 9A, 9B, 10-13, 14A, 14B, 15-17, 18A, 18B, 19A, 19B, 20-21)

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
- ☒ Formal
- ☐ Informal

**6. Additional Papers Enclosed**

- ☐ Information Disclosure Statement (37 C.F.R. Section 1.98)
- ☐ Forms PTO-1449 (PTO/SB/08A (2 pages) and 08B.
- ☐ Copy of Declaration of Biological Deposit with attached copy of ATCC Receipt filed in parent application .
- ☒ Copy of 38 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823), 4 pages of Submission of "Sequence Listing," and Diskette containing the Sequence Listing.
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☒ Other: Initial Information Data Sheet (5 pages).

**7. Declaration or Oath (including power of attorney)**

- ☒ Executed Combined Declaration and Powers of Attorney were filed in prior application 10/175,696, copies of which are enclosed (4 pages).

**8. Assignment**

- ☒ A copy of the executed Assignments of the invention to Millennium Pharmaceuticals, Inc. is attached, together with a copy of the Recordation Form Cover Sheet as filed in the parent application 10/175,696 on September 3, 2002 at Reel 013244, Frame 0405 (7 pages).

Practitioner's Docket No. : MPI02-107CN1M

9. **Fee Calculation (37 C.F.R. Section 1.16)**

A. ☒ Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$770.00
Total Claims (37 C.F.R. Section 1.16(c))	19	- 20 =	0	\$18.00	\$0.00
Independent Claims (37 C.F.R. Section 1.16(b))	2	- 3 =	0	\$86.00	\$0.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	No	\$290.00			\$0.00

**Filing Fee Calculation      \$770.00**

- ☐ Amendment canceling extra claims is enclosed.  
☐ Amendment deleting multiple-dependencies is enclosed.  
☐ Fee for extra claims is not being paid at this time.

10. **Method of Payment of Fees**

- ☐ Check in the amount of \$ \_\_\_\_\_ .  
☒ Charge Account No. 501668 in the amount of \$770.00  
A duplicate of this transmittal is attached.

Practitioner's Docket No. : MPI02-107CN1M

**11. Authorization to Charge Additional Fees**

- ☒ The Commissioner is hereby authorized to charge the following additional fees, where applicable, by this paper and during the entire pendency of this application to Account No. 501668.
- ☒ 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
- ☒ 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
- ☒ 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- ☒ 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).
- ☒ 37 C.F.R. Section 1.17 (application processing fees)
- ☐ 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

**12. Instructions as to Overpayment**

- ☒ Credit Account No. 501668.
- ☐ Refund

**13. Maintenance of Copendency of Prior Application**

The parent application (U.S. Serial Number 10/175,696 filed June 20, 2002) of the present application is currently pending.

February 11, 2004

MILLENNIUM PHARMACEUTICALS, INC.

By Janice M. Klunder  
Janice M. Klunder  
Attorney/Agent for Applicant  
Registration No. 41,121  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-551-3699  
Facsimile - 617 551 8820

- ☒ **Statement Where No Further Pages Added**